Wegovy sales double to boost Novo Nordisk's fourth quarter but slower growth predicted
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.
Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
A slowdown in Google's cloud-computing sales helped drag down Alphabet's overall revenue growth to its lowest rate since 2023. Shares tumbled about 7% ...
Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...
The company predicted operating profit for 2025 to climb between 19% and 27%, compared to growth of 26% last year.
Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...
Danish healthcare company Novo Nordisk A/S (NVO)reported Wednesday that its fiscal 2024 net profit climbed 21 percent to 100.9 ...
Financial report for the period 1 January 2024 to 31 December 2024 Operating profit increased by 25% in Danish kroner and by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback